Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Other Working Capital Changes (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Other Working Capital Changes for 9 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes changed N/A to $4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 million, a N/A change, with the full-year FY2025 number at $4.7 million, up 2689.07% from a year prior.
  • Other Working Capital Changes was $4.9 million for Q4 2025 at Soleno Therapeutics, up from -$528000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $4.9 million in Q4 2025 to a low of -$3.1 million in Q2 2025.